Table 3 Diverse agents that regulate the negative regulators of NFATc1 in osteolclastogenesis
Agent | Mechanism | Cells | Animals | Administered dose | References | |
|---|---|---|---|---|---|---|
In vitro | In vivo | |||||
UKT | Decreased Blimp-1 expression and elevated Bcl-6 expression | RAW264.7 cell | CD-1 mice | 50–500 μg/mL | N/A | Fang et al. (2022) |
AGR | Inhibited Blimp-1 expression and activated Bcl-6 expression | BMMs (C57BL/6 mice) | C57BL/6 mice | 1.25–10 μM | 10 mg/kg | Cao et al. (2021) |
Gs | Attenuated the degradation of IRF8 and downregulated NFATc1 expression | RAW264.7 cell | N/A | 10–50 μg/mL | N/A | Jin et al. (2023a) |
PTE | Decreased Blimp-1 expression and increased IRF8 levels | BMMs (C57BL/6 mice) | C57BL/6 mice | 6.125–50 μg/mL | 30 mg/kg | Zhang et al. (2022) |
IL-10 | Inhibited MEG3 expression and increased IRF8 levels | RAW264.7 cell BMMs (C57BL/6 mice) | C57BL/6 mice | 100Â ng/mL | N/A | Gao et al. (2022) |